Molecular Imaging Approaches in Dementia
Year: 2021
Type: review
Abstract: The increasing prevalence of dementia worldwide places a high demand on healthcare providers to perform a diagnostic work-up in relatively early stages of the disease, given that the pathologic process usually begins decades before symptoms are evident. Structural imaging is recommended to rule out other disorders and can only provide diagnosis in a late stage with limited specificity. Where PET imaging previously focused on the spatial pattern of hypometabolism, the past decade has seen the development of novel tracers to demonstrate characteristic protein abnormalities. Molecular imaging using PET/SPECT is able to show amyloid and tau deposition in Alzheimer disease and dopamine depletion in parkinsonian disorders starting decades before symptom onset. Novel tracers for neuroinflammation and synaptic density are being developed to further unravel the molecular pathologic characteristics of dementia disorders. In this article, the authors review the current status of established and emerging PET tracers in a diagnostic setting and also their value as prognostic markers in research studies and outcome measures for clinical trials in Alzheimer disease.
Source: Radiology
Institutions: The University of Melbourne, University of Pittsburgh, Amsterdam University Medical Centers, University College London, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Geneva, University Hospital of Geneva, Lawrence Berkeley National Laboratory, University of California, Berkeley, Karolinska University Hospital, Karolinska Institutet
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3122040678
